Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer


Por: Ciruelos, E, Diaz, M, Isla, M, Lopez, R, Bernabe, R, Gonzalez, E, Cirauqui, B, Coves, J, Morales, S, Arcediano, A, Barneto, I, Cerezuela, P, Illarramendi, J, Morales, C and Ponce, S

Publicada: 1 nov 2019 Ahead of Print: 1 sep 2019
Categoría: Oncology

Resumen:
Objectives Although new therapies against metastatic cancer have been developed in recent decades, chemotherapy is still an important treatment option. Prolonged treatment and side-effects are often discouraging for patients, and in many cases, therapy is only palliative, not curative. This study explores patient preference for oral or intravenous (IV) chemotherapy in the treatment of metastatic breast or lung cancer. Methods It is a descriptive, open label, multicentre, nation-wide study, in which a 16-item questionnaire consisting of single-choice questions scored on a 5-point Likert scale was administered to patients in a single visit, and another 11-item questionnaire was self-administered by the patient's oncologist. Results A total of 131 breast and lung cancer specialists at 64 hospitals enrolled 412 patients (lung cancer = 161; breast cancer = 251). To be eligible, patients must have already received IV therapy and at least 2 cycles of oral chemotherapy. Most (77%) patients expressed preference for oral therapy. Most considered their daily life was less disrupted with tablets (70.4%), had no trouble swallowing them (86.9%), and were not concerned about forgetting to take them (56.8%). Half (56.3%) were worried about problems related to drug infusion with IV therapy, 61.7% were concerned about nurses failing to find a suitable vein, and 63.1% were dissatisfied with hospital waiting times. A uniform response was obtained from both samples of patients. Conclusion Convenience, ease of administration, fewer side effects and better quality of life tilt the balance towards oral drug administration.

Filiaciones:
Ciruelos, E:
 Hosp Univ 12 Octubre, Av Cordoba S-N, Madrid 28041, Spain

:
 Hosp Univ San Juan, Alicante, Spain

Isla, M:
 Hosp Clin Univ Lozano Blesa, Zaragoza, Spain

Lopez, R:
 Hosp Clin Univ Valladolid, Valladolid, Spain

Bernabe, R:
 Hosp Univ Nuestra Senora Rocio, Seville, Spain

Gonzalez, E:
 Hosp Virgen Nieves, Granada, Spain

Cirauqui, B:
 ICO Badalona, Badalona, Spain

Coves, J:
 Hosp Univ Son Llatzer, Palma De Mallorca, Spain

Morales, S:
 Hosp Arnau Vilanova, Lleida, Spain

Arcediano, A:
 Hosp Univ Guadalajara, Guadalajara, Spain

Barneto, I:
 Hosp Prov Reina Sofia, Cordoba, Spain

Cerezuela, P:
 Hosp Gen Univ Santa Lucia, Cartagena, Spain

Illarramendi, J:
 Complejo Hosp Navarra, Pamplona, Spain

Morales, C:
 Hosp Prov Reina Sofia, Cordoba, Spain

Ponce, S:
 Hosp Univ 12 Octubre, Av Cordoba S-N, Madrid 28041, Spain
ISSN: 09615423





EUROPEAN JOURNAL OF CANCER CARE
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 28 Número: 6
Páginas:
WOS Id: 000488527700001
ID de PubMed: 31571304

MÉTRICAS